ARV-Based Prevention

P001: Progress in HIV cascade in Russia from 2011 to 2019
Pokrovskaya, A*; Popova, A; Suvorova, Z; Dementieva, L; Pokrovsky, V (Moscow, Russian Federation)
PDF

P002: Side effects of antiretroviral therapy and their association with adherence among postpartum Malawian women
Whittaker, M*; Woodd, S; van Lettow, M; van Oosterhout, J; Tippett Barr, B; Kim, E; Schouten, E; Auld, A; Kalua, T; Jahn, A; Landes, M (London, UK)
Video

P003: Maintaining medical care for PrEP users via home sampling during the COVID-19 shutdown in Switzerland: Checkpoint@home
Hampel, B*; Drescher, S; Baumann, B; Borso, D; Hijatzi, L; Fehr, J (Zurich, Switzerland)
PDF

P004: Disclosure of PrEP status and its association with online sexual networking among men who have sex with men in Hong Kong
Lau, Y; Wong, N; Lee, S* (Hong Kong, Hong Kong)
PDF

P005: Cork University Hospital clinical audit: the management of pregnancies in HIV-positive women and the safety and efficacy of ART during pregnancy
Meek, J*; Rizzo, G; Murphy, E (Cork, Ireland)
Video

Treatment Strategies: New Treatments And Targets

O416: Single doses of MK-8507, a novel HIV-1 NNRTI, reduced HIV viral load for at least a week
Ankrom, W*; Schuermann, D; Jackson Rudd, D; Schaeffer, A; De Lepeleire, I; Friedman, E; Robberechts, M; Zhang, S; Keicher, C; Hofmann, J; Stoch, A; Iwamoto, M (West Point, PA, USA)
PDF

P006: Cabotegravir + rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results
Swindells, S*; Lutz, T; Van Zyl, L; Porteiro, N; Benn, P; Huang, J; Harrington, C; Hove, K; Ford, S; Talarico, C; Chounta, V; Crauwels, H; Van Solingen-Ristea, R; Vanveggel, S; Margolis, D; Smith, K; Vandermeulen, K; Spreen, W (Omaha, NE, USA)
PDF       Audio

P007: Multicenter, open-label, post-authorization safety study (PASS) of elsulfavirine (Elpida^®) used in the first-line therapy for HIV-1 infected patients added to standard ART (NNRTI + two NRTIs)
Yakubova, E; Kravchenko, A; Shimonova, T; Bessarab, T; Sizova, N; Stepanova, E; Pokrovskaya, A; Kuimova, U; Kuznetsova, A; Radzikhovskaya, M; Pozdnyakova, L; Ulyanova, Y; Gusev, D; Yakovlev, A; Kovelenov, A; Inozemtseva, E; Baranovsky, S; Arsienko, R; Remeeva, J; Corritori, S; Savchuk, N; Dukes, I; Weichert, A; Richman, D; Murphy, R* (Chicago, IL, USA)
PDF

P008: Social, psychological, and treatment-related challenges of a new HIV diagnosis in old age
Spinelli, F*; Okoli, C; de los Rios, P; Nwokolo, N; Short, D (Research Triangle Park, NC, USA)
PDF       Audio

P009: HIV cure trials acceptability, representations and ethical issues among patients living with HIV: a qualitative study
Lesage, S*; Gilles, I; Storari, C; Peytremann Bridevaux, I; Barbieux, C; Vittoz, L; Calmy, A (Lausanne, Switzerland)
PDF

P010: Efficacy and safety of dolutegravir in treatment-naive people living with HIV-1 stratified by age: meta-analysis of 48-week results from ARIA, FLAMINGO, SINGLE, and SPRING-2
Spinelli, F*; Prakash, M; Slater, J; van der Kolk, M; Bassani, N; Grove, R; Wynne, B; van Wyk, J; Clark, A (Research Triangle Park, NC, USA)
PDF       Audio

P011: Comparability of 48-week efficacy and safety of cabotegravir + rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients
Chounta, V*; Snedecor, S; Wu, S; Van de Velde, N (Brentford, UK)
PDF       Audio

P012: Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)
Chounta, V*; Wu, S; Upadhyay, O; Griffith, S; Harrington, C; Orkin, C; Swindells, S; Spreen, W; Margolis, D (Brentford, UK)
PDF       Audio

P013: Experience from a real-life cohort: outcome of 984 HIV infected patients treated with bictegravir/emtricitabine/tenofovir alafenamide in Hospital Clinic, Barcelona
Rojas Liévano, J*; Berrocal, L; Inciarte, A; De la Mora, L; González-Cordón, A; Martínez-Rebollar, M; Laguno, M; Torres, B; Ugarte, A; Chivite, I; Leal, L; Ambrosioni, J; Blanco, J; Martínez Chamorro, E;
Mallolas, J (Barcelona, Spain)
PDF

P014: Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and physicians in western Europe
Akinwunmi, B; Buchenberger, D; Scherzer, J; Bode, M; Rizzini, P; Vecchio, F; Roustand, L; Nachbaur, G; Finkielsztej, L; Chounta, V*; van de Velde, N (Brentford, UK)
PDF       Audio

P015: Long-acting treatments: people’s expectations and attending physicians’ preparedness. Are we ready to manage it?
Celesia, M*; Ceccarelli, M; Trezzi, M; Tzannis, A; Errico, M; Cinque, P; Focà, E; Ripamonti, D; Martini, S; Nozza, S; Gervasoni, C; Dentone, C; Cenderello, G; Calcagno, A; Orofino, G; Cattelan, A; Tacconelli, E; Vichi, F; Saracino, A; Lo Caputo, S; De Socio, G; Guadagnino, G; Parruti, G; Cingolani, A; Borderi, M; Mussini, C; D’ettorre, G; Maggi, P; Quirino, T; Madeddu, G; Capetti, A; Di Biagio, A; Cacopardo, B; Celesia, B (Milano, Italy)
PDF

P016: What about me? The unmet needs of men who have sex with women and differences in HIV treatment experiences, perceptions, and behaviors by gender and sexual orientation in 25 countries
Okoli, C*; Van de Velde, N; Brough, G; Hardy, W; Corbelli, G; Allan, B; Muchenje, M; Castellanos, E; Young, B; Eremin, A; Ramothwala, P; de los Rios, P (Brentford, UK)
PDF       Audio

P017: Outcomes for women receiving long-acting cabotegravir + rilpivirine monthly and every 2 months: ATLAS-2M study Week 48 results
Benn, P*; Quercia, R; Hudson, K; Wang, Y; Chounta, V; Talarico, C; Ford, S; Cutrell, A; Margolis, D; Van Solingen-Ristea, R; Vanveggel, S; Van Eygen, V; Polli, J; de Ruiter, A; Smith, K; Spreen, W (Brentford, UK)
PDF       Audio

P018: Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection: 3-year results from the GEMINI studies
Cahn, P*; Sierra-Madero, J; Arribas, J; Antinori, A; Ortiz, R; Clarke, A; Hung, C; Rockstroh, J; Girard, P; Sievers, J; Man, C; Urbaityte, R; Underwood, M; Pappa, K; Smith, K; Gartland, M; Aboud, M; van Wyk, J; Wynne, B (Buenos Aires, Argentina)
PDF       Audio

P019: Clinical significance of gp120 polymorphisms, temsavir IC50FC, and HIV-1 subtype in BRIGHTE
Gartland, M*; Ackerman, P; Mannino, F; Garside, L; Clark, A; Pierce, A; Krystal, M; Llamoso, C; Lataillade, M (Research Triangle Park, NC, USA)
PDF       Audio

Treatment Strategies: Target Populations

P020: Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed PLWH: the STAT study
Rolle, C*; Berhe, M; Singh, T; Ortiz, R; Wurapa, A; Ramgopal, M; Leone, P; Matthews, J; Dalessandro, M; Underwood, M; Angelis, K; Wynne, B; Merrill, D; Nguyen, C; van Wyk, J (Orlando, FL, USA)
PDF       Audio

P021: Fostemsavir exposure-response relationships in treatment-experienced HIV patients
Parasrampuria, R*; Goyal, N; Moore, K; Ackerman, P; Llamoso, C; Barker, K; Magee, M (Collegeville, PA, USA)
PDF       Audio

P022: Model-based approach of dose selection and optimal pharmacokinetics sampling of fostemsavir for pediatric patients with multidrug resistant HIV-1 infection
Thakkar, N*; Magee, M; Moore, K; Ackerman, P; Chabria, S; Llamoso, C; Goyal, N (Upper Providence, PA, USA)
PDF       Audio

P023: Virological, immunological response and safety of initial antiretroviral treatment in HIV late presenters in HIV Spanish National Cohort
Bisbal, O*; Rava, M; Domínguez-Domínguez, L; Jarrín, I; Iribarren, J; Gutierrez, F; García Rosado, D; Górgolas, M; Peraire, J; Poveda, E; Rubio, R; Moreno, S (Madrid, Spain)
PDF

P024: HIV-DNA decrease during treatment in primary HIV-1 infection: a randomised clinical trial with three different drug regimens
Nozza, S*; Gabrielli, A; Bernasconi, D; Marchetti, G; Calcagno, A; Ripamonti, D; Antinori, A; Squillace, N; Cauda, R; Parisi, M; Muscatello, A; Bandera, A; Tambussi, G; Rusconi, S (Milan, Italy)
PDF

P025: Clinical profile, antiretroviral drug exposure and virological status of perinatally HIV-infected adolescents transferred from paediatric to adult HIV care: 20 years of experience in a public hospital in Buenos Aires, Argentina
Cordova, E*; Arazi Caillaud, S; Rodriguez, C (Buenos Aires, Argentina)
PDF

P027: Efficacy and durability of raltegravir-based dual therapy
Cassol, C*; Dolci, G; Emiliozzi, A; Gennari, W; Bruzzone, B; Vicenti, I; Micheli, V; Borghi, V; Callegaro, A; Monno, L; Rusconi, S; Laghetti, P; Lombardi, F; Zazzi, M; Fabbiani, M (Siena, Italy)
PDF

P028: Effect of online education on physician knowledge and confidence for the immunological drivers of depletion and recovery for CD4 T cells and implications of non-response in HIV-positive individuals
Duffey, J*; Voorn, S; Sutton, R (Matlock, UK)
PDF       Audio

Treatment Strategies: Adherence

P029: Impact of adherence on viral suppression with bictegravir and dolutegravir (DTG) containing triple therapy in clinical practice
Sax, P*; Althoff, K; Eron, J; Radtchenko, J; Diaz-Cuervo, H; Mounzer, K; Ramgopal, M; Santiago, S; Elion, R (Boston, MA, USA)
PDF       Video

P030: Cost-utility analysis of long-acting cabotegravir + rilpivirine for the treatment of HIV infection in the United Kingdom
Parker, B; Chounta, V; Gait, C; Hayward, O; Hunjan, M; Schroeder, M; Jacob, I; Van de Velde, N* (London, UK)
PDF       Audio

P031: Beyond viral load: exploring mediating factors for the gap in optimal self-rated health by adherence status among older adults living with HIV
Spinelli, F*; Okoli, C; de los Rios, P; Nwokolo, N; Short, D (Research Triangle Park, NC, USA)
PDF       Audio

P032: Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US
Sutton, S*; Wang, X; Diaz-Cuervo, H; Magagnoli, J (Columbia, SC, USA)
PDF

P033: Self-care and involvement in managed care among people living with HIV in Europe
Okoli, C*; Corbelli, G; Brough, G; Van de Velde, N; de los Rios, P (Brentford, UK)
PDF       Audio

P034: Role of patient’s pathway on HIV service organisation and adherence to treatment
Lopatina, Y*; Momotyuk, G; Zakowicz, A (Kyiv, Ukraine)
PDF       Video

P035: The relationship between the quality of care perceived by the patient and adherence to antiretroviral treatment
Gimeno-García, A*; Montero-Hernández, C; Franco-Moreno, A; Arponen, S; García-Carrasco, É; Alejos, B; Corps-Fernández, D; Varillas-Delgado, D; Galindo-Jara, P; García-Navarro, M (Torrejón de Ardoz, Spain)
PDF

Treatment Strategies: Simplification And Switch Studies

P036: Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide, from a boosted protease inhibitor-based regimen
Rockstroh, J*; Molina, J; Post, F; Fox, J; Koenig, E; Daar, E; DeJesus, E; Ruane, P; Crofoot, G; Oguchi, G; Creticos, C; Liu, A; Andreatta, K; Graham, H; Brainard, D; Martin, H (Bonn, Germany)
Video

P037: Long-term treatment efficacy and safety following switch to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF): Week 144 results of the DRIVE-SHIFT trial
Kumar, P*; Johnson, M; Molina, J; Rizzardini, G; Cahn, P; Bickel, M; Wan, H; Morais, C; Sklar, P; Greaves, W (Washington, DC, USA)
PDF       Video

P038: Switching to bictegravir/emtricitabine/tenofovir alafenamide in adults aged >65 years or older: Week 72 results from an international, phase IIIb, open-label trial
Maggiolo, F*; Rizzardini, G; Molina, J; Pulido, F; De Wit, S; Vandekerckhove, L; Berenguer, J; D’Antoni, M; Blair, C; Chuck, S; Piontkowsky, D; Martin, H; Haubrich, R; McNicholl, I; Gallant, J (Bergamo, Italy)
PDF       Video

P039: 12-months outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected patients: real-world data from the German JUNGLE cohort
Noe, S*; Ummard-Berger, K; Hillenbrand, H; Beer, D; Wyen, C; Pauli, R; Postel, N; Dymek, K; Westermayer, B; Scherzer, J (Munich, Germany)
PDF

P040: Early discontinuation of ABC/3TC/DTG and BIC/TAF/FTC single-tablet regimens: a real-life multicentre cohort study
Lagi, F*; Botta, A; Arturo, C; Chiara, P; Fabbiani, M; Di Giambenedetto, S; Borghi, V; Mussini, C; Bartoloni, A; Gaetana, S (Firenze, Italy)
PDF

P041: Real-world experience using bictegravir/emtricitabine/tenofovir-alafenamide (B/F/TAF) in a Scottish HIV cohort
Proud, E*; Murphy, C (Glasgow, UK)
PDF

P042: Does tuberculosis coinfection increase the risk of being on second-line antiretroviral therapy in Tanzania?
Mollel, E*; Masanja, R; Todd, J; Msuya, S; Mahande, M (Kilimanjaro, Tanzania)
PDF

P043: Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in an observational Italian cohort: interim analysis of DIAMANTE (TMC114FD1HTX4011) study
Antinori, A; Vergori, A; Rizzardini, G; Ripamonti, D*; Esposito, V; Rusconi, S; Manzillo, E; Orofino, G; Andreoni, M; Lazzarin, A; Madeddu, G; Cascio, A; Uglietti, A; Termini, R; Portaro, M; Mancusi, D (Cologno Monzese, Italy)
PDF       Video

P044: Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) + lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany
Postel, N*; Schneeweiss, S; Wyen, C; Schabaz, F; Degen, O; Weinberg, G; Sabranski, M; Ummard-Berger, K; Dymek, K; Westermayer, B; Scherzer, J (Munich, Germany)
PDF

P045: Dual HIV treatment in experienced HIV patients
Battagin, G*; Parisi, S; Giordani, M; Paolo, F; Mascarello, M; Del Punta, V; Luise, D; Timillero, L; Manfrin, V (Vicenza, Italy)
PDF

Treatment Strategies: Other

O112: Weight gain plateaus at 24-months follow-up for ART-experienced patients that switched to dolutegravir in a Nigerian early adopter cohort
Campbell, J*; Abudiore, O; Amamilo, I; Harwell, J; Middlecote, C; Conroy, J; Eigege, W; Otubu, N; Jiboye, J; Anomnachi, L; Lufadeju, F; Amole, C; Wiwa, O; Agbaji, O; Anweh, D; Akanmu, S (Boston, MA, USA)
PDF

O415: Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks
Molina, J*; Yazdanpanah, Y; Afani Saud, A; Bettacchi, C; Chahin Anania, C; DeJesus, E; Klopfer, S; Grandhi, A; Eves, K; Hepler, D; Robertson, M; Hwang, C; Hanna, G; Correll, T (Paris, France)
PDF

P046: Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the global BICSTaR study
Spinner, C*; Stoehr, A; Wong, A; de Wet, J; Zeggagh, J; Hocqueloux, L; van Welzen, B; Heinzkill, M; Sahali, S; Torres Cornejo, A; Ramroth, H; Haubrich, R; Thorpe, D; Kim, C (Munich, Germany)
PDF       Video

P047: Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naïve adults with HIV-1
Orkin, C*; Molina, J; Yazdanpanah, Y; Chahin Anania, C; DeJesus, E; Eron, J; Klopfer, S; Grandhi, A; Xu, J; Eves, K; Hepler, D; Robertson, M; Hwang, C; Hanna, G; Correll, T (London, UK)
PDF       Video

P048: Renal safety through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naïve adults with HIV-1
Post, F*; McMullan, C; DiPerri, G; Molina, J; Klopfer, S; Grandhi, A; Eves, K; Hepler, D; Hwang, C; Correll, T (London, UK)
PDF       Video

P049: The occurrence of hypersensitivity reaction and hepatotoxicity in individuals receiving integrase strand transfer inhibitors: results from the EuroSIDA study
Pelchen-Matthews, A*; Larsen, J; Shepherd, L; Begovac, J; Pedersen, K; Curtis, L; De Wit, S; Horban, A; Jablonowska, E; Johnson, M; Khromova, I; Losso, M; Nielsen, L; Ridolfo, A; Schmied, B; Stephan, C; Yust, I; Vannappagari, V; Roen, A; Raben, D; Kirk, O; Peters, L; Mocroft, A (London, UK)
PDF

P050: Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3^rd agent in HIV-1+ patients over 24 months – Results from the German TAFNES cohort study
Stellbrink, H*; Scholten, S; Hillenbrand, H; Knechten, H; Jessen, H; Schreiber, S; Goerner, K; Haubrich, R; Heinzkill, M (Hamburg, Germany)
PDF

P051: Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain
Ruiz Alguero, M; Alejos, B*; García Yubero, C; Riera, M; Iribarren, J; Asensi, V; Pasquau, F; Galera, C; Jarrín, I; Suárez-García, I (Madrid, Spain)
PDF

P052: Systematic review of patient-reported outcome measures (PROMs) used in clinical trials of HIV-infected adults on combination antiretroviral therapy (cART)
Normandin, A*; Mate, K; Houlding, E; Engler, K; Cox, J; Kronfli, N; Lessard, D; Lebouché, B (Montreal, Canada)
PDF

P053: Patient-reported outcomes after one year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide in PLWH: the BICSTaR cohort
Knechten, H; Stephan, C; Waizmann, M; Brunetta, J; Trottier, B; Bonnet, F; Duvivier, C; van Welzen, B*; Mack, F; Tossonian, H; Thorpe, D; Torres Cornejo, A; Marongiu, A; Curbelo, R (Aachen, Germany)
PDF       Video

P054: Narrative medicine as PROs to understand living with HIV from patients’ experiences: TMC114FD1HTX4011 – DIAMANTE study
Antinori, A; Vergori, A*; Esposito, V; Carleo, M; Andreoni, M; Malagnino, V; Rusconi, S; Castelli, F; Focà, E; Manzillo, E; Pizzella, T; Cappuccio, A; Reale, L; Fiorencis, A; Marini, M; Portaro, M; Mancusi, D; Termini, R; Uglietti, A (Rome, Italy)
PDF       Video

P055: Perceptions of HIV-infected men who have sex with men as regards functional cure of HIV infection
Kwan, T*; Chan, C; Wong, N; Lee, S (Shatin, Hong Kong)
PDF

P056: Durability of F/TAF in a large cohort of PLWH seen for care in Italy
Vergori, A*; Cozzi Lepri, A; Gianotti, N; Calcagno, A; Guaraldi, G; Orofino, G; Moioli, M; Gentile, I; Loredana, S; Cicalini, S; d’Arminio Monforte, A; Antinori, A (Rome, Italy)
PDF       Video

P057: Improving methods for patient-reported outcome (PRO) analyses in observational HIV studies
Williams, L*; Marongiu, A; Reilly, G; Heinzkill, M; Haubrich, R; Castles, R; Filippidis, F; Ramroth, H (London, UK)
PDF

P058: Factors associated with quality of sexual life among women with HIV and HCV
Rodriguez, S*; Huntingdon, B; Juraskova, I; Preau, M; Etemadi, F; Galano, E; Carrieri, P; Bessonneau, P; Chassany, O; Duracinsky, M; Fofana Dara, A (Paris, France)
PDF

Opportunistic Infections

P059: Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes
Savchenko, M*; Panteleev, A (Saint-Petersburg, Russian Federation)
PDF

P060: Progressive multifocal leukoencephalopathy, still a challenge in the combined antiretroviral therapy era
Ianache, I; Olaru, A; Radoi, R; Nica, M; Tardei, G; Ene, L; Oprea, C* (Bucharest, Romania)
PDF       Audio

Co-Morbidities And Complications Of Disease And/Or Treatment: Ageing

P061: Increased levels of immune activation and exhaustion in vertically HIV-1 infected young adults
Tarancón-Díez, L*; Carrasco, I; Vázquez-Alejo, E; Jiménez de Ory, S; Sainz, T; Apilanez, M; Rojo, P; Guillén, S; Ramos, J; Muñoz-Fernández, M; Navarro, M (Madrid, Spain)
PDF

P062: Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient reported outcomes
Sabin, C*; Okhai, H; Dhairyawan, R; Haag, K; Burns, F; Gilson, R; Sherr, L; Tariq, S (London, UK)
PDF

P063: Impact of baseline comorbidities on ART persistence and effectiveness in PLWH receiving F/TAF-based regimens: final 24-month results from the German TAFNES cohort study
Scholten, S*; Hillenbrand, H; Postel, N; Knechten, H; Pauli, R; Jessen, H; Emmerich, C; Pehlivan, C; Albuquerque, B; Haubrich, R; Stellbrink, H (Köln, Germany)
PDF       Audio

P064: Frailty of Greek PLWHIV in association with clinical markers and psychological factors: preliminary results of a nationwide study
Tsakona, D*; Xochelli, A; Chini, M; Meliou, M; Psichogiou, M; Basoulis, D; Panagopoulos, P; Petrakis, V; Karamanidou, C (Thessaloniki, Greece)
PDF       Video

Co-Morbidities And Complications Of Disease And/Or Treatment: Cardiovascular

P065: The association of incidental coronary calcification and imaging covariates in people living with HIV. Results from the Liverpool Multiparametric Imaging Collaboration
Heseltine, T*; Murray, S; Brinksman, P; Fisher, M; McCarthy, G; Chaponda, M; Khoo, S (Liverpool, UK)
PDF

P066: Examining associations between HIV status and high blood pressure (hypertension) in a high HIV prevalence population in Manicaland, east Zimbabwe: a cross-sectional study of adults
Davis, K*; Moorhouse, L; Maswera, R; Nyamukapa, C; Smit, M; Gregson, S (London, UK)
PDF       Video

P067: Comparing the prevalence of hypertension by HIV status in sub-Saharan African adults: a systematic review and meta-analyses of cross-sectional studies
Davis, K*; Perez Guzman, P; Gregson, S; Smit, M (London, UK)
PDF       Video

P068: The prevalence and risk factors for peripheral artery disease in chronic kidney disease in HIV-infected persons
Viskovic, K; Marinelli, A; Nedeljko, K; Javoric, I; Bogdanic, N*; Zekan, S; Begovac, J (Zagreb, Croatia)
PDF

P069: Influence of CD4+/CD8+ ratio on early age of stroke in persons living with HIV: a single university centre study in Portugal
Pais-de-Lacerda, A*; Moreira, S; Simões Coelho, P (Lisboa, Portugal)
PDF

P070: Left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients: prevalence and associations with clinical characteristics
Basoulis, D; Athanasiadi, E; Bonou, M; Masoura, C; Skouloudi, M; Kapelios, C; Barbetseas, J; Psichogiou, M* (Athens, Greece)
PDF

P071: Transcranial Doppler pulsatility index as a marker of endothelial dysfunction, especially useful when before persistently low CD4+/CD8+ ratios
Pais-de-Lacerda, A*; Lira, A; Soares, F; Badura, R; Valadas, E; Simões Coelho, P; Oliveira, V (Lisboa, Portugal)
PDF

Co-Morbidities And Complications Of Disease And/Or Treatment: Malignancies

P072: A 10-year case series of HHV8-related diseases in an ethnically diverse HIV cohort: is human herpesvirus 8 level a clue to the underlying pathology?
Oliveira, A*; Patel, N; Sanei, F; Sudhanva, M; Childs, K; Hamlyn, E (London, UK)
PDF

P073: Results of HPV testing from three anatomical locations among men with different HIV status and sexual behaviour
Popova, A*; Domonova, E; Pokrovskaya, A; Shipulina, O; Pokrovskiy, V (Moscow, Russian Federation)
PDF

Co-Morbidities And Complications Of Disease And/Or Treatment: Metabolic

O111: Fat distribution and density in people living with HIV with ≥5% weight gain
Guaraldi, G*; Draisci, S; Milic, J; Carli, F; Besutti, G; Bassoli, C; Raimondi, A; Ciusa, G; Ligabue, G; Mussini, C; Erlandson, K; Brown, T; Lake, J (Modena, Italy)
PDF

P074: NAFLD with significant fibrosis in people living with HIV informs the natural history of cardiovascular disease
Milic, J*; Cervo, A; Carli, F; Ciusa, G; Menozzi, M; Dolci, G; Bacca, E; Rogati, C; Tutone, M; Mazzola, G; Mussini, C; Sebastiani, G (Modena, Italy)
PDF

P075: Differential effects of raltegravir, dolutegravir and bictegravir on human adipocytes
Domingo, P*; Quesada-López, T; Villarroya, J; Gutierrez, M; Mur, I; Corbacho, N; Mateo, G; Domingo, J; Villarroya, F; Giralt, M (Barcelona, Spain)
PDF

P076: Genetic markers of NAFLD associated with NASH in HIV-infected patients
Busca, C; Sanchez-Conde, M; Arias, P; Rico, M; Montejano, R; Martin-Carbonero, L; Bernardino, J; Pérez-Valero, I; Valencia, E; Moreno, V; Mican, R; Olveira, A; González-Garcia, J; Montes-Ramirez, M* (Madrid, Spain)
PDF

P077: Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide
Lowman, E*; Hardigan, P; Unger, N; Lee, N (Oakland Park, FL, USA)
PDF       Video

P078: Hepatic fibrosis in people with HIV and non-alcoholic fatty liver disease: baseline data from an open-label, feasibility randomised trial of maraviroc plus optimised background therapy (OBT) versus OBT alone
Bradshaw, D*; Abramowicz, I; Bremner, S; Gilleece, Y; Fedele, S; Kirk, S; Clarke, C; Williams, S; Jennings, L; Scanlon, D; Lambert, P; Verma, S; Orkin, C; Nelson, M; Gompels, M; Fox, A; Clarke, E; Chadwick, D; Perry, N (Brighton, UK)
Video

P079: The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: central nervous system penetration effectiveness (CPE) score evolution from baseline to 2-year follow-up
Damas, J*; Nadin, I; Calmy, A; Assal, F; Hauser, C; Hasse, B; Schlosser, L; Tarr, P; Stoeckle, M; Kunze, U; Schmid, P; Hundsberger, T; Di Benedetto, C; Rossi, E; Ledergerber, B; Du Pasquier, R; Darling, K; Cavassini, M (Lausanne, Switzerland)
Video

Co-Morbidities And Complications Of Disease And/Or Treatment: Neurological

P080: Clinical utility of β-amyloid PET imaging in people living with HIV with cognitive symptoms
Vera, J*; Eftychiou, N; Schuerer, M; Rullmann, M; Barthel, H; Sabri, O; Gisslen, M; Zetterberg, H; Blennow, K; O’Brien, C; Banerjee, S; Dizdarevic, S (Brighton, UK)
PDF

P081: CNS HIV viral escape syndrome presenting with persistent HIV viremia
Schinold, M*; Kogilwaimath, S; Fitzgerald, N; Pozniak, C (Saskatoon, Canada)
PDF

P082: Utility of Pittsburgh Sleep Quality Index (PSQI) in PLWH for assessment and monitoring of sleep disturbance in a community HIV clinic
Goorney, B*; Waddicar, A; (Salford, UK)
PDF       Audio

P083: Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
Tiraboschi, J*; Prieto, P; Saumoy, M; Silva, A; Imaz, A; Scevola, S; Fernandez-Olivares, G; Navarro-Alcaraz, A; Piatti, C; Podzamczer, D (L’Hospitalet, Barcelona, Spain)
PDF

P084: Perception of Spanish HIV physicians towards diagnosis and management of neuropsychiatric comorbidities in people with HIV
Pérez Valero, I*; Blanch Andreu, J; Martínez Chamorro, E (Madrid, Spain)
PDF

Co-Morbidities And Complications Of Disease And/Or Treatment: Other

P085: Important factors related to the sexual quality of life among men living with HIV/AIDS
Etemadi, F*; Bessonneau, P; Huntingdon, B; Fofana Dara, A; Juraskova, I; Da Silva, M; Thomas, R; Griffi, J; Thonon, F; Chassany, O; Rodriguez, S; Duracinsky, M (Paris, France)
PDF

P086: Meeting the fourth 90: evaluating the mental health of an urban population of people living with HIV in a Greater London clinic
Mortimer, H*; Fowler-Williams, C; Dunin-Skrzynno, S; Cormack, I (London, UK)
PDF

P087: Gastrointestinal (GI) adverse events with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) through Week 96: an EMERALD post-hoc analysis
Dunn, K*; Baugh, B; Bejou, N; Luo, D; Campbell, J; Seyedkazemi, S (Titusville, NJ, USA)
Video

P088: Prevalence of HIV-related stigma among participants of the Swiss HIV Cohort Study: a pilot study
Kampouri, E*; Damas, J; Jackson-Perry, D; Cobos Manuel, I; Scherrer, A; Cavassini, M; Darling, K (Lausanne, Switzerland)
PDF

P089: The prevalence of major comorbidities among people living with HIV in Croatia
Benkovic, I; Mocibob, L; Zekan, S; Lukas, D; Bogdanic, N; Begovac, J* (Zagreb, Croatia)
PDF

P090: Frailty prevalence in people living with HIV from three HIV clinics in Lisbon
Flor de Lima, B*; Silva, A; Pedro, D; Leitão, I; Pintado Maury, I; Caixeiro, M; Macedo, A (Amadora, Portugal)
PDF

P091: Importance of screening for depression in people living with HIV in Ukraine
Lopatina, Y; Momotyuk, G; Zakowicz, A*; Kalandia, H (Amsterdam, Netherlands)
PDF       Video

P092: Analysis of adherence to HIV-positive quality of care indicators and their impact on health-related quality of life: a Spanish cross-sectional study
Gimeno-García, A*; Montero-Hernández, C; Franco-Moreno, A; Arponen, S; García-Carrasco, É; Corps-Fernández, D; Alejos, B; Varillas-Delgado, D; Galindo-Jara, P; García-Navarro, M (Torrejón de Ardoz, Spain)
PDF

P093: Real-world characterisation of the Portuguese population living with HIV who initiated raltegravir-based regimen between 2015 and 2017 – REALITY study
Serrão, R; Mansinho, K; Maltez, F; Marques, N; Carvalho, A; Pazos, R; Zagalo, A; Mendez, J; Neves, I; Oliveira, J; Pacheco, P; Correia de Abreu, R; Miranda, A*; Camacho, A; Paixão, L; Almeida, J (Lisboa, Portugal)
PDF       Audio

Viral Hepatitis

P094: Phylodynamics of sexually acquired HCV-3a in HIV co-infected patients in Hong Kong
Kwan, T*; Wong, B; Chan, D; Wong, N; Lee, S (Shatin, Hong Kong)
PDF

P095: Efficacy, safety and convenience of integrase strand transfer inhibitors-based ART regimens in people living with HIV coinfected with hepatitis C and/or B viruses
Carosi, G*; Rich, S; Prosperi, M; Mazzini, N; Nasta, P; Quiros Roldan, E; Di Filippo, E; Cauda, R; Saracino, A; Angarano, G; Vichi, F; Esperti, S; Sighinolfi, L; Segala, D; Lapdaula, G; Bonfanti, P; Fornabaio, C (Brescia, Italy)
PDF

P096: Hepatitis C infection and treatment outcomes in the direct-acting antiviral era
Jewsbury, S*; Newton, P; Tomkins, A; Garner, A; Teo, S; Ahmad, S; Saxon, C; Ward, C; Prince, M; Lee, V (Manchester, UK)
PDF

P097: Features of HIV and HCV epidemics in central part of Ukraine
Koval, T*; Marchenko, O; Sabinina, O; Koval, A (Poltava, Ukraine)
PDF

Clinical Pharmacology

P098: Evaluation and clinical application of fostemsavir co-administration with tuberculosis medications
Moore, K*; Nguyen, D; Tai, G; Magee, M; Gorycki, P; Lee, T; Ackerman, P; Llamoso, C; Clark, A (Research Triangle Park, NC, USA)
PDF       Audio

P099: Safety, tolerability, and pharmacokinetics following single- and multiple-dose administration of the novel NNRTI MK-8507 with a midazolam interaction arm
Ankrom, W*; Schaeffer, A; Panebianco, D; Friedman, E; Tomek, C; Stoch, A; Iwamoto, M (Kenilworth, NJ, USA)
PDF       Video

P100: The clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide – Real-world data from the German IQVIA prescription database
Umland, T*; Stellbrink, H; Calvo, M; Zahn, A (Hamburg, Germany)
PDF       Video

P101: Development and clinical validation of an liquid chromatography with ultraviolet detection method to quantify dolutegravir in dried blood spots
Akinloye, A*; Adeagbo, B; Bolaji, O; Olagunju, A (Ile-Ife, Nigeria)
PDF

P102: Fostemsavir and ethinyl estradiol drug interaction: clinical application for coadministration
Nwokolo, N*; Post, E; Magee, M; Ackerman, P; Llamoso, C; Moore, K (Brentford, UK)
PDF       Audio

Community Initiatives

P103: Awareness and perception of accuracy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA) in Italy and correlation with the level of confidence in reference physicians
Cingolani, A*; Tavelli, A; Calvino, G; Maggiolo, F; Girardi, E; Cozzi-Lepri, A; Perziano, A; Camposeragna, A; Gagliardini, R; Nozza, S; Antinori, A; d’Arminio Monforte, A (Rome, Italy)
PDF

P104: What’s trending in Asia? Drawing inferences from online HIV support seeking patterns of risk groups in Asia using regional Adam’s Love and TemanTeman.org big datasets
Anand, T; Nitpolprasert, C* (Bangkok, Thailand)
PDF

P105: HIV prevention among MSM in Japan: current opinions on achieving the first 90 among Japanese MSM
Anand, T; Nitpolprasert, C*; Shirasaka, T; Iwatani, Y; Yokomaku, Y; Imahashi, M; Kaneko, N; Iwahashi, K; Ikushima, Y; Aoki, R; Ishida, T; Shiono, S; Yamaguchi, M; Takemura, K; Iwamoto, A (Bangkok, Thailand)
PDF      Video

P107: Thinking outside the box: evaluating the impact of a virtual classroom model to deliver HIV primary care education to physicians and nurse practitioners across Saskatchewan, Canada
Stewart, K; Kogilwaimath, S*; Galambos, A (Saskatoon, Canada)
Video

P109: Sexual behaviours and associated factors among men living with HIV in Istanbul, Turkey
Kumbasar Karaosmanoglu, H*; Altuntas Aydin, O; Yesilbag, Z (Istanbul, Turkey)
PDF

P110: Capacity building for youth coalitions, critical for sustaining gains in HIV prevention sphere
Ita, D*; Alaka, O; Durueke, F (Lagos, Nigeria)
PDF       Audio

Models Of Care: Cost Effectiveness And Evaluation Of Delivery And Coverage

P111: EmERGE: feasibility and uptake of a co-designed digital health supported pathway of care for people living with medically stable HIV
Whetham, J*; Jones, C; Bremner, S; Apers, L; Begovac, J; Borges, M; Leon, A; Vera, J; Zekan, S; West, B; Chausa, P; Gomez, E; Garcia, F; EmERGE Consortium (Brighton, UK)
PDF

P112: Differences in patient-reported outcomes among single- and multi-tablet regimens
Degroote, S*; Vanden Bulcke, C; Vogelaers, D; Vandekerckhove, L (Ghent, Belgium)
Video

P113: Community responses on variability in the frequency of patient visits to HIV clinics in the EU
Greenhalgh, F; West, B*; Von Lingen, A; Dutarte, M; Whetham, J (Edinburgh, UK)
PDF       Audio

P114: Modelling the future of HIV in Turkey: disease implications of improving prevention, diagnosis and treatment
Yaylali, E*; Gökengin, D; Korten, V; Tabak, F; Ünal, S; Erdogan, Z; Çalışır, F; Özelgün, B; Şahin, T (Istanbul, Turkey)
PDF       Video

P115: To 90-90-90 and beyond: feasibility and clinical outcomes of same-day ART initiation among PLHIV in a real-life, middle-income setting
Barletta, J*; Jaume, M; De Ilzarbe, M; Bruno, D; Romero, A; Tokumoto, N; Vigo, G; Díaz, L; Cando, O; Rolón, M (Buenos Aires, Argentina)
PDF       Audio

P116: Community responses about access to and importance of telemedicine by PLHIV and clinical staff in the EU
Greenhalgh, F; West, B*; Von Lingen, A; Dutarte, M; Whetham, J (Edinburgh, UK)
PDF       Audio

P117: Ensuring continuity of care for people living with HIV in five European countries: the efficiency of the EmERGE platform
Beck, E*; Mandalia, S; Yfantopoulos, P; Leon, A; Merino, M; Garcia, F; Wittevrongel, M; Apers, L; Benkovic, I; Zekan, S; Begovac, J; Cunha, A; Teofilo, E; Rodrigues, G; Borges, M; Fatz, D; Vera, J; Whetham, J (London, UK)
PDF

P118: To 90-90-90 and beyond: a community-focused multimodal, interdisciplinary intervention to optimise continuum of care among recently diagnosed PLHIV in a middle-income setting
De Ilzarbe, M; Bruno, D; Jaume, M; Barletta, J; Romero, A; Tokumoto, N; Vigo, G; Díaz, L; Cando, O; Rolón, M* (Buenos Aires, Argentina)
PDF       Audio

P119: Comprehensive retention to care model: results of the pilot in Krasnoyarsk, Russia 2016-2019
Kandlen, K*; Chuykov, A; Boiko, A; Burdina, Y; Zakowicz, A; Mironova, N (Saint Petersburg, Russian Federation)
PDF       Video

Virology And Immunology

O324: Lenacapavir resistance analysis in a phase Ib clinical proof-of-concept study
Margot, N*; Ram, R; Parvangada, P; Martin, R; Hyland, R; Rhee, M; Callebaut, C (Foster City, CA, USA)
PDF

O443: Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults infected with HIV: a phase III trial
Mohapi, L; Osiyemi, O*; Supparatpinyo, K; Ratanasuwan, W; Molina, J; Dagan, R; Tamms, G; Sterling, T; Zhang, Y; Hartzel, J; Pedley, A; Kan, Y; Hurtado, K; Buchwald, U; Musey, L; Simon, J (West Palm Beach, FL, USA)
PDF

P120: Islatravir selects for HIV-1 variants in MT4-GFP cells that profoundly reduce replicative capacity in peripheral blood mononuclear cells
Diamond, T*; Ngo, W; Xu, M; Goh, S; Rodriguez, S; Lai, M; Asante-Appiah, E; Grobler, J (Kenilworth, NJ, USA)
PDF       Video

P121: Impact of resistance to antiretroviral drugs on predicted HIV-1 susceptibility to current single-tablet regimens (STRs)
Rossetti, B*; Di Carlo, D; Fabbiani, M; Stella, G; Vicenti, I; Maggiolo, F; Gennari, W; Francisci, D; Santoro, M; Zazzi, M (Siena, Italy)
PDF

P122: Impact of genetic variation of the APOBEC3G gene on HIV RNA, T-cell counts, markers of inflammation and clinical events
Domínguez-Domínguez, L*; Reekie, J; Leung, P; Zucco, A; Novak, R; Gilson, R; Stephan, C; Rupasinghe, D; Helleberg, M; MacPherson, C; Lundgren, J; Murray, D; INSIGHT START Study Group (Copenhagen, Denmark)
PDF

P123: Sustained viral suppression after switch to bictegravir/emtricitabine/tenofovir alafenamide among clinical trial participants with preexisting M184V/I
Andreatta, K*; Acosta, R; D’Antoni, M; Porter, D; Chang, S; Martin, R; Willkom, M; McNicholl, I; Gallant, J; Pikora, C; Graham, H; Collins, S; Martin, H; White, K (Foster City, CA, USA)
PDF       Audio

P124: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F
Acosta, R*; Andreatta, K; D’Antoni, M; Collins, S; Martin, H; White, K (Foster City, CA, USA)
PDF       Audio

P125: Development of integrase inhibitor resistance under first-line treatment with bictegravir
Stoll, M; Braun, P*; Wiesmann, F; Knechten, H (Aachen, Germany)
PDF

P126: Barriers for participation in HIV vaccine trials among general population in Argentina: first interim survey
Cecchini, D*; Ballivian, J; Feld, D; Cassetti, I (Buenos Aires, Argentina)
PDF

Late Presenters

P127: Improving the HIV testing cascade: adequate identification of patients with HIV indicator conditions in hospitals by electronic registration systems
Jordans, C*; Hensley, K; Vogel, M; van Kampen, J; Boucher, C; Mollema, F; Gisolf, J; El Moussaoui, R; Hermanides, G; van der Valk, M; Finkenflügel, R; Rijnders, B; Verbon, A; Rokx, C (Rotterdam, Netherlands)
PDF       Audio

P128: Routine, automated and clinician independent universal screening of HIV infection in an emergency department: reducing late presentation by overcoming barriers to testing
Vaz Pinto, I*; Guimaraes, M; Castro, V; Santos, C; Galiano, A; Friaes, J; Bilé, A (Alcabideche, Portugal)
PDF       Audio

P129: Effectiveness and persistence of F/TAF-containing regimens (E/C/F/TAF, R/F/TAF or F/TAF+3^rd agent) in late and very late presenters: final 24-month results from the German TAFNES cohort study
Postel, N*; Jessen, H; Pauli, R; Hillenbrand, H; Heuchel, T; Rieke, A; Knechten, H; Emmerich, C; Schreiber, S; Mack, F; Haubrich, R; Stellbrink, H (Munich, Germany)
PDF       Audio

P130: Late presenters of HIV infection during COVID-19 pandemic
Panagopoulos, P; Petrakis, V*; Kyrgiannaki, V; Kriaraki, Z; Papazoglou, D (Alexandroupolis, Greece)
PDF

COVID-19

O242: STI and HIV testing to break the chain of infection: local innovation in the midst of COVID-19
Wood, C*; Ahmad, S; Jewsbury, S; Redmond, M; Saxon, C; Sukthankar, A; Thomas, D; Ward, C; McQuillan, O (Manchester, UK)
PDF

O422: Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol (UK): A prospective observational study
Geretti, A*; Stockdale, A; Kelly, S; Villa, G; Turtle, L; Semple, M; Sabin, C (Liverpool, UK)
PDF

O444: SARS-CoV-2 infection in pregnancy and newborn in a Spanish multicentric cohort (GESNEO-COVID)
Carrasco, I*; Muñoz, M; Vigil, S; Aguilera, D; Riaza, M; Sanz, O; Pareja, M; Baña, A; Sanchez Luna, M; Navarro, M (Madrid, Spain)
PDF
P131: Resilience and frailty in people living with HIV during the lockdown experience in Italy in March-May 2020: are they two complementary constructs?
Guaraldi, G*; Milic, J; Ciusa, G; Raimondi, A; Cuomo, G; Carli, F; Mussini, C (Modena, Italy)
PDF

P132: Impact of COVID pandemic among men who have sex with men living with HIV during COVID lockdown in Argentina
Ballivian, J*; Cecchini, D; Alcaide, M; Abbamonte, J; Jones, D; Cassetti, I (Buenos Aires, Argentina)
PDF

P133: COVIDApp: a health application as an innovative strategy for the management of the COVID-19 pandemic in long-term care facilities
Echeverría, P*; Mas, M; Puig, J; Isnard, M; Massot, M; Vedia, C; Peiró, R; Ordorica, Y; Pablo, S; Ulldemolins, M; Iruela, M; Balart, D; Ruiz, J; Herms, J; Clotet, B; Negredo, E (Barcelona, Spain)
PDF

P134: SARS-CoV2 pandemic: SARS-CoV2 seroprevalence and impact on HIV suppression in PLWH
Cuomo, G*; Bacca, E; Menozzi, M; Carli, F; Borghi, V; Guaraldi, G; Mussini, C (Modena, Italy)
PDF

P135: Prevalence of respiratory virus infections during a SARS-CoV2 epidemic
Sukach, M*; Ingiliz, P; Valin, N; Boussaid, K; Julienn, J; Chiarabini, T; Morand-Joubert, L; Gozlan, J; Schnuriger, A; Lacombe, K (Paris, France)
PDF

P136: Prophylactic dose of low-molecular-weight heparin (LMWH) might not be sufficient to mitigate the clinical scenario in patients with COVID-19 and severe pneumonia
Vergori, A*; Donno, D; Lorenzini, P; Nicastri, E; Gualano, G; Iacomi, F; Marchioni, L; Schininà, V; Cicalini, S; Agrati, C; Capobianchi, M; Girardi, E; Ippolito, G; Vaia, F; Petrosillo, N; Antinori, A; Taglietti, F (Rome, Italy)
PDF

P137: Symptoms of viral infection and polymerase chain reaction (PCR) positivity rates of SARS-CoV2 in healthcare professionals in Paris, France
Sukach, M*; Ingiliz, P; Valin, N; Barbut, F; Morand-Joubert, L; Gozlan, J; Schnuriger, A; Lacombe, K (Paris, France)
PDF

P138: Understanding how HIV testing has been affected by the COVID-19 response
Greenhalgh, F; Von Lingen, A; Cigan, B*; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)
PDF       Audio

P139: Cross-border movement restrictions during Covid-19 and foreign nationals’ access to healthcare and medicines
Greenhalgh, F; Von Lingen, A*; Cigan, B; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)
PDF       Audio

P140: The impact of COVID-19 epidemic on HIV care in Croatia
Bogdanic, N*; Zekan, S; Romih Pintar, V; Lukas, D; Begovac, J (Zagreb, Croatia)
PDF

P141: Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago
Sherer, R*; Lehmann, C; Zhu, M; Lio, J (Chicago, IL, USA)
PDF       Video

P142: Effect of first 3 months of COVID pandemic on HIV services in Greece: a short survey among HIV physicians
Lourida, G*; Leonidou, L; Psichogiou, M; Chrysanthidis, T; Protopappas, K; Katsarolis, I; Xylomenos, G; Panagopoulos, P; Chini, M; Papastamopoulos, V (Athens, Greece)
PDF

P143: Fears and perception of the risk of infection with SARS-CoV-2 in a cohort of HIV+ subjects on antiretroviral treatment in an outpatient clinic in Sicily
Ceccarelli, M*; Marino, A; Accordino, S; Lupo, G; Boscia, V; Cosentino, F; Moscatt, V; Bruno, R; Pampaloni, A; Scuderi, D; Cacopardo, B; Celesia, B (Catania, Italy)
PDF

P144: How has the COVID-19 response changed medicine deliveries for people living with or at risk of HIV?
Greenhalgh, F; Von Lingen, A; Cigan, B*; Varasi, P; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)
PDF       Audio

P145: Characterisation of PLWH with COVID-19 in a tertiary care reference centre for emerging infectious diseases in Portugal
Nunes Silva, C*; Caldas, J; Martins, A; Policarpo, S; Rocha, R; Freitas, F; Mesquita, M; Abreu, I; Graça, L; Palma Martins, P; Ceia, F; Pineiro, C; Neves, N; Silva, S; Tavares, M; Serrão, R; Sarmento, A (Porto, Portugal)
PDF       Audio

P146: Assessing the mental health of people living with HIV in Scotland during COVID-19
Hirono, J*; Sparling, N (Edinburgh, UK)
PDF

P147: Characteristics and outcomes of inpatient COVID-19 infections in people living with HIV
Jewsbury, S*; Garner, A; Houston, J; Polden, M; Saxon, C; Tomkins, A; Lee, V (Manchester, UK)
PDF

P148: SARS-CoV-2 infection in HIV patients: we anticipated a worse scenario
Bastos, L*; Pocinho, S; Machado, A; Guerreiro, G; Domingos, J; Miranda, C; Goncalves, E; Fonseca, C; Mansinho, K (Lisboa, Portugal)
PDF

P149: Understanding how the COVID-19 response affects the quality of care services for people living with HIV and communities affected by HIV
Greenhalgh, F; Von Lingen, A*; Cigan, B; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)
PDF     Audio